

A3  
cmld.

--16. The use according to claim 6 for increasing NGF and BDNF.--

### REMARKS

By the foregoing amendment to the specification, a cross-reference has been inserted beneath the title on Page 1.

Claim 7 has been amended to eliminate its multiple dependency.


New Claims 12-16 are directed to the subject matter excised from Claim 7.

Attached hereto is a "marked-up" version of the change made to Claim 7 by the foregoing amendment.

Early and favorable consideration of the claims is respectfully awaited.

Respectfully submitted,

Novartis Pharmaceuticals Corporation  
Patent and Trademark Dept.  
564 Morris Avenue  
Summit, NJ 07901-1027  
(908) 522-6921

  
\_\_\_\_\_  
Joseph J. Borgvian  
Agent for Applicants  
Reg. No. 26,631

Date: September 18, 2001

Encl.: "Marked-up" version of the  
change made to Claim 7

VERSION WITH MARKINGS TO SHOW CHANGES MADE

Claim 7 has been amended as follows:

7. The use according to ~~any one of claims 1 to 6~~ claim 1 for increasing NGF and BDNF.